![Edward Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Edward Smith
Directeur Général chez
Aristar Capital Management LLC
Fortune : - $ au 31/05/2026
Profil
Edward Byron Smith was the founder of Brightline Capital Management LLC, founded in 2005, where the title held was Managing Member from 2005 to 2014.
Current jobs include Executive Chairman at Population Bio, Inc.; Director at Elusys Therapeutics, Inc. since 2010; Director at Pelican Therapeutics, Inc.; Managing Member at Brightline Ventures I B LLC; Managing Member at Brightline Ventures.
I C LLC; Managing Member at Aristar Capital Management LLC since 2015; and Managing Member at Brightline Ventures.
I LLC.
Former jobs include Director, Chief Executive & Financial Officer at Agritech Worldwide, Inc. in 2017; Independent Director at Scorpius Holdings, Inc. from 2010 to 2026; Analyst at P&S Capital Partners LLC in 2004; Analyst at Credit Suisse First Boston LLC in 1998; and Associate at GTCR LLC in 2000.
Education includes an MBA from Harvard Business School conferred in 2003 and an undergraduate degree from Harvard College conferred in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/04/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Edward Smith
| Sociétés | Poste | Début |
|---|---|---|
Brightline Ventures I LLC | Corporate Officer/Principal | - |
Brightline Ventures I B LLC | Corporate Officer/Principal | - |
Brightline Ventures I C LLC | Corporate Officer/Principal | - |
Aristar Capital Management LLC
 Aristar Capital Management LLC Investment ManagersFinance Aristar Capital Mgmt invests in companies located in the United States. The firm focuses on a broad range of sectors and industries. It participates in early stage capital requirements. | Directeur Général | 01/01/2015 |
Pelican Therapeutics, Inc.
 Pelican Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic biological agents for immuno-oncology combinations | Directeur/Membre du Conseil | - |
Population Bio, Inc.
 Population Bio, Inc. Medical SpecialtiesHealth Technology Develops therapies and diagnostics | Président | - |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. BiotechnologyHealth Technology Develops immune-stimulatory and immune-derived therapies for the treatment of infectious diseases | Directeur/Membre du Conseil | 01/11/2010 |
Anciens postes connus de Edward Smith
| Sociétés | Poste | Fin |
|---|---|---|
| SCORPIUS HOLDINGS, INC. | Directeur/Membre du Conseil | 23/04/2026 |
| AGRITECH WORLDWIDE, INC. | Directeur Général | 14/07/2017 |
| ░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Edward Smith
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
53
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Agritech Worldwide, Inc.
 Agritech Worldwide, Inc. Food: Major DiversifiedConsumer Non-Durables Manufactures multifunctional dietary fiber ingredients for the food industry | Consumer Non-Durables |
P&S Capital Partners LLC
 P&S Capital Partners LLC Investment ManagersFinance P&S Capital Partners invests primarily in the stocks of US small- cap and large-cap companies in the utilities, consumer services, producer manufacturing and consumer durables sectors. The firm tends to acquire assets that are trading at a low price-to-earnings multiple compared to a stock's intrinsic value. P&S Capital Partners maintains a very high turnover rate. The Gracie Credit Opportunities Fund is a hedge fund that invests globally in investment grade fixed-income securities including high-yield, stressed and distressed credits. The Fund employs a fixed-income long/short investment strategy. | Finance |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. BiotechnologyHealth Technology Develops immune-stimulatory and immune-derived therapies for the treatment of infectious diseases | Health Technology |
Credit Suisse First Boston LLC
 Credit Suisse First Boston LLC Investment Banks/BrokersFinance Provides global investment banking services | Finance |
Scorpius Holdings, Inc.
 Scorpius Holdings, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of therapies | Health Technology |
Population Bio, Inc.
Population Bio, Inc. Medical SpecialtiesHealth Technology Develops therapies and diagnostics | Health Technology |
Brightline Ventures I B LLC | |
Brightline Ventures I C LLC | |
Pelican Therapeutics, Inc.
Pelican Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic biological agents for immuno-oncology combinations | Health Technology |
Aristar Capital Management LLC
Aristar Capital Management LLC Investment ManagersFinance Aristar Capital Mgmt invests in companies located in the United States. The firm focuses on a broad range of sectors and industries. It participates in early stage capital requirements. | Finance |
GTCR LLC
 GTCR LLC Investment ManagersFinance GTCR invests in companies located in North America. The firm focuses on financial services & technology, healthcare, information services & technology, TMT and business service sectors. It provides financing in the form of equity for corporate carve-outs, add-on acquisitions, buyouts and growth transactions with an investment size of USD 250 – 600 million. The firm also acquires minority interests. | Finance |
Brightline Capital Management LLC
 Brightline Capital Management LLC Investment ManagersFinance Brightline’s overall investment philosophy is value-driven and based on disciplined, rigorous fundamental analysis and research. The firm generally looks for companies with strong fundamentals that are selling at prices that represent a discount to our conservative estimate of the company’s long-run cash flows. They primarily invest with a bottom-up perspective, focusing on the individual company business model. Most investments have historically been made through US financial markets in US-based companies. Their investment strategy is focused on generating superior absolute returns. | Finance |
Brightline Ventures I LLC | |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
